Status: Recruiting
Prospective Observational Study of Outcomes After Gemcitabine, Docetaxel, Melphalan, and Carboplatin With Autologous Stem Cell Transplantation in Pediatric Relapsed/Refractory Germ Cell Tumors
To collect information about treatment outcomes in pediatric and adolescent patients with relapsed/refractory germ cells tumors who receive GemDMC with an ASCT.
Participants needed: 30
Trial details
Age: 21+Biological sex: AllType: ObservationalSponsor: M.D. Anderson Cancer CenterUpdated: Jun 23, 2026Locations: 1
Eligibility criteria
Male or female participants, greater than 1 month of age up to 21 years old. Neo... [+2]
Participants who do not or did not receive GemDMC as part of the conditioning re...